Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach

J Virol. 2018 Oct 12;92(21):e01002-18. doi: 10.1128/JVI.01002-18. Print 2018 Nov 1.

Abstract

Dengue virus (DENV) is the most prevalent mosquito-transmitted viral pathogen in humans. The recently licensed dengue vaccine has major weaknesses. Therefore, there is an urgent need to develop improved dengue vaccines. Here, we report a virion assembly-defective DENV as a vaccine platform. DENV containing an amino acid deletion (K188) in nonstructural protein 2A (NS2A) is fully competent in viral RNA replication but is completely defective in virion assembly. When trans-complemented with wild-type NS2A protein, the virion assembly defect could be rescued, generating pseudoinfectious virus (PIVNS2A) that could initiate single-round infection. The trans-complementation efficiency could be significantly improved through selection for adaptive mutations, leading to high-yield PIVNS2A production, with titers of >107 infectious-focus units (IFU)/ml. Mice immunized with a single dose of PIVNS2A elicited strong T cell immune responses and neutralization antibodies and were protected from wild-type-virus challenge. Collectively, the results proved the concept of using assembly-defective virus as a vaccine approach. The study also solved the technical bottleneck in producing high yields of PIVNS2A vaccine. The technology could be applicable to vaccine development for other viral pathogens.IMPORTANCE Many flaviviruses are significant human pathogens that pose global threats to public health. Although licensed vaccines are available for yellow fever, Japanese encephalitis, tick-borne encephalitis, and dengue viruses, new approaches are needed to develop improved vaccines. Using dengue virus as a model, we developed a vaccine platform using a virion assembly-defective virus. We show that such an assembly-defective virus could be rescued to higher titers and infect cells for a single round. Mice immunized with the assembly-defective virus were protected from wild-type-virus infection. This vaccine approach could be applicable to other viral pathogens.

Keywords: NS2A; dengue virus; flavivirus vaccine; trans-complementation; viral assembly.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Defective Viruses / genetics
  • Defective Viruses / pathogenicity*
  • Dengue / genetics
  • Dengue / immunology
  • Dengue / virology*
  • Dengue Vaccines / immunology*
  • Dengue Virus / genetics
  • Dengue Virus / pathogenicity*
  • Female
  • Humans
  • Male
  • Mice
  • Mutation
  • RNA, Viral
  • Viral Nonstructural Proteins / genetics
  • Viral Nonstructural Proteins / immunology*
  • Virus Assembly*
  • Virus Replication*

Substances

  • Antibodies, Neutralizing
  • Dengue Vaccines
  • NS2A protein, Dengue virus type 2
  • RNA, Viral
  • Viral Nonstructural Proteins